Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFINE: PF-07055480 Gene Therapy in Adult Males With Hemophilia A
jRCT2043210021Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
Phase 3, open-label, single-arm trial of giroctocogene fitelparvovec in hemophilia A, sponsored by Pfizer. Primary endpoint: Annualized bleeding rate (ABR). Started Jun 2021; status: active, not recruiting.
02
Drugs
giroctocogene fitelparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2043210021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043210021.